NSEAllotment of Securities7 Jul 2026 · 7 Jul 2026, 06:05 pm

Allotment of Securities

Bliss GVS Pharma Limited · BLISSGVS

✦ AI Summary

Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 187,750 securities pursuant to ESOP/ESPS at its meeting held on July 07, 2026, increasing the issued, subscribed & paid-up share capital of the Company.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 187750 securities pursuant to ESOP/ESPS at its meeting held on July 07, 2026

Attachments (1)

📄

BLISSGVS_07072026180521_Outcome_of_ESOP_Allotment_Committee.pdf

pdf

Download →
View document text
July 07, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India Ltd. BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Dear Sir/Madam, Subject: Allotment of Shares under Bliss GVS Pharma Limited – Employee Stock Options Plan, 2019 We like to inform you that the ESOP Allotment Committee of the Company, at its meeting held today i.e. July 07, 2026, has approved the allotment of 1,87,750 equity shares of the face value of Re. 1/- each to the eligible employee who has exercised their stock options under Bliss GVS Pharma Limited–Employee Stock Option Plan 2019 (‘Bliss GVS ESOP-2019’). Consequent to the aforesaid allotment, issued, subscribed & paid-up share capital of the Company has increased as under: From To 10,60,56,223 equity shares of Re. 1/- each 10,62,43,972 equity shares of Re. 1/- each aggregating Rs. 10,60,56,223/- aggregating Rs. 10,62,43,972/- In terms of Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 the details of shares allotted as above are given in ‘Annexure-I’ to this intimation. Kindly take the above information on record. Thank you. Yours faithfully, For Bliss GVS Pharma Limited Aditi Bhatt Company Secretary Encl: As above ‘Annexure – I’ Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 Company Name and address of Registered Bliss GVS Pharma Limited Office Add: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400072 Name of the Stock Exchanges on which the BSE Limited Company’s shares are listed The National Stock Exchange of India Limited Filing date of the statement referred in 14/02/2020 regulation 10(b) of the SEBI (Share Based Employee Benefits) Regulations, 2014 read with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange Filing Number, if any Application No: BSE – 106063 NSE – 23188 In-Principle Approval Letter: BSE: DCS/FL/DS/ESOP-IP/542/2019-20 dated February 27, 2020 NSE: NSE/LIST/23188 dated March 04, 2020 Title of the Scheme pursuant to which Bliss GVS Pharma Limited–Employee Stock shares are issued, if any Option Plan, 2019 Kind of security to be listed Equity Shares Par value of the shares Re. 1/- per share Date of issue of shares July 07, 2026 Number of shares issued 1,87,750 Share Certificate No., if applicable Not Applicable Distinctive number of the share, if 10,60,56,223 to 10,62,43,972 (both inclusive) applicable ISIN Number of the shares if issued in INE416D01022 Demat Exercise price per share Rs. 43/- per share Premium per share Rs. 42/- per share Total Issued shares after this issue 10,62,43,972 Total Issued share capital after this issue Rs. 10,62,43,972 /- Details of any lock-in on the shares Lock in for a period of 6 (six) months from the date of allotment of Equity Shares. Date of expiry of lock-in January 06, 2027 Whether shares are identical in all respects All equity shares of the Company allotted to existing shares, if not, when will they pursuant to the exercise of stock options become identical? shall rank pari passu with the existing equity shares of the Company Details of listing fees, if payable Not applicable